Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-880 in Type 1 Diabetes with a Kidney Transplant
NCT06832410Phase 3Recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Mar 2025
- Primary completion
- Sep 2026
- Modality
- Beta Cells, Stem Cell Therapies
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of zimislecel in type 1 diabetes mellitus (T1D), sponsored by Vertex Pharmaceuticals. Primary endpoint: Proportion of Participants who are Insulin Independent at 1 year. Started Mar 2025; status: recruiting.
02
Drugs
zimislecel
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06832410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06832410.